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Abstract
The formation of insoluble amyloid fibrils is associated with an array of devastating human diseases. Dialysis-related
amyloidosis (DRA) is a severe complication of hemodialysis that results in the progressive destruction of the bones and
joints. Elevated concentrations of b2-microglobulin (b2m) in the serum of subjects on hemodialysis promote the formation
of amyloid fibrils in the osteoarticular tissues, but the cellular basis for the destruction of these tissues in DRA is poorly
understood. In this study we performed a systematic analysis of the interaction of monomeric and fibrillar b2m with primary
human cells of the types present in the synovial joints of subjects with DRA. Building upon observations that macrophages
infiltrate b2m amyloid deposits in vivo we demonstrate that monocytes, the precursors of macrophages, cannot degrade
b2m fibrils, and that both monomeric b2m and fibrillar b2m are cytotoxic to these cells. b2m fibrils also impair the formation
of bone resorbing osteoclasts from monocytes and reduce the viability of osteoblasts, the cell type that produces bone. As a
consequence, we predict that b2m amyloid will disrupt the remodelling of the bone, which is critical for the maintenance of
this tissue. Moreover, we show that b2m fibrils reduce the viability of chondrocytes, rationalizing the loss of cartilage in DRA.
Together, our observations demonstrate that b2m cytotoxicity has multiple cellular targets in the osteoarticular tissues and
is likely to be a key factor in the bone and joint destruction characteristic of DRA.
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Introduction
The formation of insoluble amyloid fibrils is associated with a
spectrum of devastating human diseases, many of which are
characterised by tissue destruction [1]. One such disorder is
dialysis-related amyloidosis (DRA), a debilitating complication of
long-term hemodialysis [2,3]. The culprit protein of DRA is b2-
microglubulin (b2m) [4,5], the non-covalent light-chain of cell
surface major histocompatibility complex (MHC) class I molecules
[6]. Upon dissociation from MHC molecules, b2m is normally
removed from the bloodstream by the kidneys [6]. The normal
serum concentration of b2m is 1–3 mg/ml but, in end stage renal
disease, neither the kidney nor the dialysis membrane can
efficiently remove b2m from the circulation and serum levels
increase by up to 60 fold and can exceed 100 mg/ml [2,3,7]. At
these elevated concentrations, b2m forms amyloid fibrils in the
osteoarticular tissues resulting in arthropathy, cartilage destruc-
tion, bone cysts leading to pathologic fractures, carpal tunnel
syndrome and spondyloarthropathy [2–6,8,9].
b2m fibril formation is promoted by collagen and the
glycosaminoglycans (GAGs) chondroitin-sulfate and heparin [10–
14]. Collagen and chondroitin-sulfate are abundant in osteoartic-
ular tissues, rationalizing the deposition of b2m amyloid at these
sites, whereas heparin is an anti-coagulant used in hemodialysis.
b2m lacking the N-terminal six residues of the mature protein
(DN6b2m) constitutes #30% of the b2m in ex vivo DRA amyloid
[15]. Unlike full-length wild type (WT) b2m, DN6b2m forms
amyloid fibrils de novo at neutral pH in vitro, a process that is
enhanced by GAGs [12,13,16–18]. DN6b2m fibrils also cross-seed
fibril formation with WT b2m and can convert WT b2m into an
amyloidogenic state, suggesting that DN6b2m could initiate fibril
formation in vivo [17,18].
In contrast to the increasing knowledge of the mechanism of
b2m fibril assembly in vitro [6,19], how b2m amyloid causes skeletal
morbidity in DRA is poorly understood. Macrophages infiltrate
b2m amyloid deposits and have been implicated in the develop-
ment of symptomatic DRA [20–22]. Cells of the monocyte/
macrophage lineage are precursors of osteoclasts, which may be
responsible for osteolytic lesions in DRA [23–27]. Indeed, human
b2m has been shown to promote osteoclastogenesis from murine
macrophages [28], but whether monomeric or fibrillar b2m species
promote human osteoclast formation is not known. Since b2m
fibrils generated in vitro are cytotoxic to some cultured cell lines
[29], b2m amyloid formation could also cause bone and joint
destruction via cytotoxicity to cell types that are responsible for the
maintenance of the osteoarticular tissues.
Herein we perform a systematic comparison of the effects of
monomeric and fibrillar b2m on primary human cells relevant to
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the pathology of DRA (monocytes, osteoblasts and chondrocytes).
Our data do not support a role for monomeric or fibrillar b2m in
osteoclast formation by human monocytes, but instead show that
b2m monomer and fibril preparations are cytotoxic to monocytes,
osteoblasts and chondrocytes and hence b2m cytotoxicity may be
an important factor in the bone and joint destruction associated
with DRA.
Results
Generation of b2m fibrils in vitro at a physiologically
relevant pH
Recombinant human WT b2m and DN6b2m were expressed in
E. coli and purified [12,30,31]. Size-exclusion chromatography
(SEC) confirmed that both proteins are predominantly monomeric
at pH 7.3 ($98% of WT b2m; ,96% of DN6b2m), although
,4% of DN6b2m was dimeric (Fig. 1A and B). Neither protein
was recognized by the A11 or WO1 antibodies (Fig. 1C), which
bind generic epitopes in cytotoxic oligomers and amyloid fibrils,
respectively [32,33].
To generate b2m fibrils at a physiologically relevant pH, and
within an experimentally tractable timescale, fibrils generated at
pH 2 from WT b2m were fragmented to produce seeds that were
then extended with DN6b2m monomer at pH 7.3 in the presence
of heparin [12]. The resultant fibrils were not recognized by the
A11 antibody, were recognized by the WO1 antibody (Fig. 1C);
bound the amyloid specific dye thioflavin-T (Fig. 1D) and
exhibited a long straight morphology when visualized by negative
stain transmission electron microscopy (TEM) (Fig. 1E) reminis-
cent of ex vivo b2m amyloid [34–36]. Moreover, we have shown
previously with Fourier transform infrared spectroscopy that fibrils
elongated from WT b2m seeds at pH 7 closely resemble ex vivo
b2m amyloid [36]. Fibrils formed from seeds elongated with a 1:9
mixture of DN6b2m and 5-(and -6)-carboxytetramethylrhoda-
mine-SE (TMR) labelled DN6b2m also had the characteristic
features of amyloid (Fig. 1C, D and F).
Human monocytes internalize, but do not degrade, b2m
fibrils
The macrophages that infiltrate b2m amyloid plaques are
present around blood vessels consistent with these cells being
derived from peripheral blood monocytes [20,37]. We, therefore,
investigated whether these cells could play a protective role in
DRA via the degradation of b2m fibrils. CD14
+ monocytes
isolated from peripheral blood were cultured in the presence of
macrophage colony stimulating factor (M-CSF), whereupon they
become adherent and develop a macrophage-like morphology.
These cells were incubated with either TMR-labelled monomeric
DN6b2m or TMR-labelled b2m fibrils. Prior to imaging by
confocal microscopy the cells were incubated with LysoTracker
green, a fluorescent probe that accumulates in acidic intracellular
compartments. After 24 hours, both monomer and fibrils were
internalized and co-localized with Lysotracker green in punctate
structures (Fig. 2A and B). The smaller puncta stained by
Lysotracker green are characteristic of lysosomes, whereas the
larger punctate structures that are most prominent in cells
incubated with fibrils may correspond to acidified phagosomes.
Indeed, this would be consistent with electron microscopy studies
of ex vivo DRA amyloid, in which macrophages were shown to
phagocytose b2m amyloid [38].
After incubation for a further 24 hours in the absence of
extracellular TMR-labelled monomeric DN6b2m or fibrils, a
pronounced decrease in intracellular fluorescence was observed for
cells that had internalized monomeric protein (Fig. 2A and C). In
contrast only a modest reduction in intracellular fluorescence
occurred in cells that had internalized b2m fibrils (Fig. 2B and D).
Thus monocytes internalize and traffic both b2m monomer and
fibrils to acidic vesicles, but only the monomeric protein is
degraded efficiently. The inability of these phagocytic cells to
degrade b2m fibrils would allow amyloid deposition to proceed
unchecked in the synovial joints of subjects with DRA.
Monomeric and fibrillar b2m do not promote osteoclast
formation
In addition to forming macrophages, monocytes can differen-
tiate into bone resorbing osteoclasts [24–26]. Since primary
human monocytes interact with both monomeric and fibrillar b2m
(Fig. 2), and human b2m monomer has been shown to stimulate
osteoclast formation from murine macrophages [28], we next
Figure 1. Analysis of monomeric and fibrillar b2-microglobulin
(b2m). Analytical size exclusion chromatography traces of 1 mg/ml full-
length wild type (WT) b2m (a) and DN6b2m (DN6) (b), obtained in
phosphate buffered saline pH 7.3 at 25uC. Monomer (m) and dimer (d)
peaks are indicated. (c) Immunoblots of monomeric and fibrillar b2m
probed with A11 anti-oligomer and WO1 anti-fibrillar antibodies. Ab1–40
oligomers were used as a positive control for the A11 antibody. (d)
Thioflavin-T fluorescence of unlabelled and TMR-labelled b2m fibrils,
error bars represent one standard deviation over 60 readings. Negative
stain transmission electron microscopy images of unlabelled (e) and
TMR labelled (f) b2m fibrils.
doi:10.1371/journal.pone.0027353.g001
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examined whether either monomeric or fibrillar b2m can promote
osteoclast formation from human monocytes. Osteoclasts are
defined as large multinucleate cells, which express high levels of
tartrate-resistant acid phosphatase (TRAP) and can resorb
artificial bone substrates [24–26]; hence each of these character-
istics were used to monitor osteoclast formation.
In a control experiment, monocytes were incubated with
receptor activator of nuclear factor-K ligand (RANKL), a
cytokine that promotes osteoclast formation [24–26]. After 14
days there were abundant large ($20 mm) cells, which stained
positive (dark pink) for TRAP in centrally located intracellular
vesicles (Fig. 3A). Many of the cells were multinucleate, as
visualised by hematoxylin staining, and they were able to resorb
the majority (,70%) of an artificial bone substrate (Fig. 3A and
B). This confirmed that under the culture conditions used in this
study osteoclasts form in 14 days. In contrast, when cells were
incubated with buffer, DN6b2m monomer or WT b2m monomer,
at concentrations (10 and 100 mg/ml) that span those observed in
the serum of subjects with DRA [2,3,7], only a small number of
multinucleate, TRAP positive cells were formed, and little of the
artificial bone substrate was resorbed (,5%) (Fig. 3A and B)
indicating that neither WT b2m nor DN6b2m monomeric
proteins promote the differentiation of human monocytes into
osteoclasts.
When monocytes were incubated with 10 mg/ml b2m fibrils
very few large multinucleate cells were formed and there was
limited resorption of the artificial bone substrate (Fig. 3A and B),
thus demonstrating that b2m fibrils do not promote osteoclast
Figure 2. Internalization and degradation of monomeric and fibrillar b2-microglobulin (b2m) by primary human monocytes.
Monocytes were incubated with 10 mg/ml of DN6b2m monomer (90% unlabelled DN6b2m, 10% TMR-labelled DN6b2m) (a) or TMR-labelled fibrils
formed from a 9:1 mixture of unlabelled: labelled DN6b2m (red, feed) for 24 hours (b). Lysosomes were visualized by staining with LysoTracker green
prior to confocal microscopy. Differential interferance contrast (DIC) images are also shown. Cells were then washed to remove non-cell associated
protein and chased for a further 24 hours before imaging again (feed +24 hour chase). The mean intracellular fluorescence of 20 cells was quantified
for cells incubated with monomeric b2m (c) and fibrillar b2m (d) before and after the 24 hour chase. Values are normalized to 100% for the
intracellular fluoresence of cells before the chase and the percentage reduction after 24 hour chase is indicated. Error bars represent the SEM; P
values differing from the PBS control were calculated by the Student’s t-test and are stated.
doi:10.1371/journal.pone.0027353.g002
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formation. Interestingly many cells did, however exhibit a
dramatic increase in TRAP positive vesicles, giving them a dark
pink appearance after staining for the enzyme (Fig. 3A). Elevated
TRAP expression has also been observed in pulmonary alveolar
macrophages that have phagocytosed microbes and other particles
[39]; therefore TRAP could be increased in monocytes due to the
internalization of b2m fibrils. Indeed after only 24 hours
incubation with b2m fibrils, the level of TRAP expression was
increased markedly (Fig. 3C).
An alternative possibility for the observed increase in TRAP
expression was that b2m fibrils may provide a partial osteoclasto-
genic signal that synergizes with other signalling molecules to
promote the formation of mature osteoclasts. In vivo osteoclasto-
genesis is promoted by RANKL, a cytokine expressed on the
surface of osteoblasts [24–26], this molecule was absent from all
but the positive control cultures. We, therefore, examined whether
b2m fibrils act in synergy with RANKL to promote osteoclast
formation. Monocytes were incubated with increasing concentra-
Figure 3. Effects of monomeric or fibrillar b2-microglobulin (b2m) on primary human monocyte differentiation into osteoclasts.
Monocytes were incubated with the indicated substances and macrophage colony-stimulating factor (M-CSF) for 14 days. RANKL induces osteoclast
formation and was used as a positive control. (a) Top row (scale bar 50 mm): cells stained for the osteoclast marker, TRAP. 2nd row (scale bar 50 mm):
TRAP stained cells were counter stained with hematoxylin to visualize cell morphology (nuclei, blue), arrows indicate large multinucleate cells.
Regions within the yellow boxes are magnified in the 3rd row (scale bar 20 mm). Bottom row (scale bar 1 mm): resorption of an osteologic substrate
by the cells treated as indicated. Resorbed areas are coloured red. (b) Resorption was quantified and results from a representative experiment are
shown. The inset shows an expansion of the first six columns. (c) Monocytes were incubated with either PBS control or b2m fibrils for 24 hours, and
then stained for TRAP (scale bar 50 mm).
doi:10.1371/journal.pone.0027353.g003
b2m Mediated Cell Death in DRA
PLoS ONE | www.plosone.org 4 November 2011 | Volume 6 | Issue 11 | e27353
tions of RANKL in either the presence or absence of 10 mg/ml
b2m fibrils and osteoclast function assessed by measuring
resoprtion of the artificial bone substrate. As expected when
monocytes were incubated with RANKL alone the number of
osteoclasts formed and resorption of the artificial bone substrate
increased as the concentration of this cytokine was increased
(Fig. 4A and B). However, when cells were incubated with
RANKL and b2m fibrils, a reduction in resorption of the artificial
bone substrate was observed relative to cells incubated with
RANKL alone (Fig. 4A and B). Thus although b2m fibrils increase
TRAP expression they do not promote osteoclast formation,
instead b2m fibrils reduce RANKL-dependent osteoclast forma-
tion.
b2m fibrils are cytotoxic to monocytes, osteoblasts and
chondrocytes
Previously we have shown that b2m fibrils are cytotoxic to the
murine macrophage cell line RAW 264.7 [29]. We therefore
investigated whether b2m fibrils are also cytotoxic to primary
human monocytes. Using the 3-(4,5-dimethyl-2-thiazolyl)-2,5-
diphenyl-2H-tetrazolium bromide (MTT) assay, a pronounced
and significant reduction in cell viability was observed for
monocytes incubated with 10 mg/ml b2m fibrils (Fig. 5A and
S1A). By contrast to the fibrils, 10 mg/ml of DN6b2m and WT
b2m had a minimal effect on the viability of monocytes (Fig. 5A,
5B, S1A and S1B). Thus fibrils are more cytotoxic than
monomeric b2m, which is consistent with our previous study of
the effect of monomeric and fibrillar b2m on the viability of cell
lines [29]. b2m fibril cytotoxicity may contribute to the failure of
monocytes to degrade b2m fibrils and could also be responsible for
the observed reduction in ostoeclast formation, as monocyte death
would prevent these cells from fusing together to form osteoclasts.
However, at 100 mg/ml, b2m fibrils reduced cell viability by
,40%, as did the monomeric forms of DN6b2m and WT b2m
(Fig. 5A and S1A), demonstrating that monomeric forms of b2m
are also cytotoxic at this concentration.
Next we investigated whether b2m could contribute to bone and
joint destruction in DRA by reducing the viability of osteoblasts
and chondrocytes, the cells that produce bone and cartilage
respectively. The association of TMR-labelled DN6b2m monomer
or b2m fibrils with primary human osteoblasts and chondrocytes
was visualized by confocal microscopy. After 24 hours, monomer-
ic TMR-labelled DN6b2m was present in punctate intracellular
structures in osteoblasts and chondrocytes, consistent with
internalisation of the protein (Fig. S2A and S3A). Similar
internalization was seen when b2m fibrils were incubated with
chondrocytes, while fibrils added to osteoblasts remained in close
proximity to the cell surface as large aggregates, with some limited
cell-associated punctate fluorescence indicative of cell association
and internalization (Fig. S2A and S3A). Our observations suggest
both cell types internalize monomeric b2m, although chondrocytes
internalize b2m-fibrils more readily than osteoblasts.
The effect of b2m monomer and fibrils on osteoblast and
chondrocyte viability was then assessed; both 10 and 100 mg/ml
b2m fibrils caused a significant reduction in the viability of
osteoblasts and chondrocytes (Fig. 5C, 5E, S2B and S3B).
DN6b2m monomer also reduced cell viability of both cell types
(Fig. 5C, 5E, S2B and S3B). In contrast to monomeric DN6b2m,
100 mg/ml of WT b2m monomer had no significant effect on
chondrocyte viability and caused only a limited decrease in
viability of osteoblasts, at the highest concentration used (Fig. 5D
and F). Taken together, these data suggest that monomeric
DN6b2m and fibrillar b2m cytotoxicity to chondrocytes and
osteoblasts are important factors in the pathology of DRA.
Figure 4. Effects of b2-microglobulin (b2m) fibrils on RANKL-
dependent osteoclast formation. Primary human monocytes were
incubated with M-CSF and the indicated concentrations of RANKL in the
presence of PBS or 10 mg/ml b2m-fibrils for 14 days and their ability to
resorb an osteologic substrate was then assessed. (a) Images of the
osteologic substrate following the removal of cells. Resorbed regions
are highlighted in red, scale bar 1 mm. (b) Resorption was quantified
and results from a representative experiment are shown. The inset
shows an expansion of the first four columns.
doi:10.1371/journal.pone.0027353.g004
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Chondrocyte cell death would be predicted to decrease formation
of new cartilage, while the reduction in osteoclast formation in
combination with the death of osteoblasts may impair bone
turnover in subjects with DRA.
Discussion
Despite the identification of b2m as the culprit protein of DRA
in 1985 [4,5], how b2m amyloid causes bone and joint destruction
in DRA remains poorly understood. In order to elucidate the
cellular basis for the pathological consequences in DRA we
performed a systematic analysis of the effects of b2m fibrils and
monomeric b2m on cell types that are present in the synovial joints
of subjects with DRA. Our data suggest that the bone and joint
destruction characteristic of DRA is a multifactorial process in
which b2m amyloid fibrils and elevated concentrations of
monomeric b2m are cytotoxic to multiple cellular targets (Fig. 6).
We demonstrate that primary human monocytes internalize,
but do not degrade, b2m fibrils. This is consistent with the
resistance of the b2m amyloid fold to lysosomal proteolysis [40,41],
but could be exacerbated by the cytotoxicity of b2m fibrils to the
monocytic precursors of macrophages. The death of macrophages
that infiltrate amyloid deposits in vivo [20–22,37], would be
predicted to prevent the clearance of b2m monomer and fibrils
allowing the continued accumulation of b2m amyloid in the
synovial joints.
Cells of the monocytic lineage are also the precursors of
osteoclasts, which in combination with osteoblasts are responsible
for bone remodelling [26]. Monomeric b2m did not promote
osteoclast formation from human monocytes. This contrasts with a
recent study in which monomeric b2m was shown to promote
osteoclast formation from murine macrophages [28], and implies
that b2m has differential effects on human and mouse cells.
Similarly, b2m fibrils did not promote the formation of bone
resorbing osteoclasts despite increased expression of TRAP, as
there was no increase in the number of multinucleate cells nor did
b2m fibrils promote the resorption of the artificial bone substrate.
Once considered just as a marker of osteoclasts, it has become
clear that TRAP has a number of important roles in both the
skeleton and the immune system, and is expressed by a number of
different cell types including macrophages [39,42]. Thus the
increase in TRAP expression in monocytes may be the result of
the activation of these cells by b2m fibrils. Moreover, we found
that b2m fibrils impaired RANKL-induced osteoclast formation.
This was presumably as a consequence of cytotoxicity to
monocytes, as fibril-induced cell death of the monocytic precursors
would be predicted to prevent these cells from fusing together to
form multinucleate osteoclasts. This reduction in osteoclast
formation, in combination with the reduction in viability of
osteoblasts caused by b2m fibrils and to a lesser extent monomeric
b2m, suggests that bone remodelling will be perturbed in DRA.
The formation of bone cysts in DRA may, therefore, be the
consequence of a reduction in the turnover of damaged bone,
rather than an increase in osteoclast activity. Moreover, the effect
of b2m fibrils on osteoclast formation and the viability of
osteoblasts may exacerbate the reduction in bone turnover that
is a common feature of renal osteodystrophy associated with
chronic kidney disease [43]. b2m fibrils were also shown to be
cytotoxic to chondrocytes, rationalizing why the formation of b2m
amyloid deposits in cartilage results in the loss of this tissue
[2,3,8,9,22], which could in turn expose the bone surface to the
cytotoxic effects of amyloid deposits.
The mechanism by which b2m fibrils kill cells is unknown,
although other amyloid fibrils have been reported to cause both
Figure 5. Effects of monomeric and fibrillar b2-microglobulin
(b2m) on primary human monocytes, osteoblasts and chon-
drocyte viability. Cells were incubated with the indicated sub-
stances for 24 hours and then their ability to reduce MTT, as a
measure of viability, was measured. (a) Effects of b2m fibrils and
DN6b2m (DN6) monomer on monocyte viability; the mean from three
donors is plotted. (b) Effects of full-length wild type (WT) b2m
monomer on monocyte viability; the mean from three donors is
plotted. (c) The effects of b2m fibrils and DN6b2m monomer on
osteoblast viability; the mean from four donors is plotted. (d) The
effect of WT b2m monomer on osteoblast viability; the mean from one
donor is plotted. (e) The effect of b2m fibrils and DN6b2m monomer
on chondrocyte viability; the mean from four donors is plotted. (f)
Effects of WT b2m monomer on chondrocyte viability, the mean from
one donor is plotted. The data from individual donors for monocytes,
osteoblasts and chondrocytes are presented in Figures S1, S2B and
S3B, respectively. Error bars represent the SEM; P values differing from
the PBS control were calculated by the Student’s t-test, * = P#0.01;
** = P#0.001.
doi:10.1371/journal.pone.0027353.g005
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necrotic and apoptopic cell death [44–46]. b2m fibrils disrupt
purified lipid membranes [29] suggesting a role for membrane
disruption in fibril-associated cytotoxicity. Since b2m fibrils were
visualized in association with monocytes, osteoblasts and chon-
drocytes in proximity to the plasma membrane and within
intracellular punctate structures, b2m fibrils could kill these cells
by disrupting the plasma membrane and/or intracellular mem-
branes. No immunoreactivity was detected by the antibody A11,
which recognises amyloid oligomers [32]. This suggests that
cytotoxicity associated with b2m fibril preparation is mediated by
the interaction of b2m fibrils with the cells.
Incubation of cells with monomeric WT b2m or DN6b2m also
resulted in reduced viability, with the DN6b2m monomer
exhibiting the greatest degree of cytotoxicity. While, no oligomers
were detected in either protein preparation as determined by SEC
and by immunoblotting with the oligomer specific antibody A11,
WT b2m can form cytotoxic non-fibrillar aggregates [47,48],
whereas the cytotoxicity of DN6b2m could reflect the increased
propensity of this truncation to aggregate or its different
conformational properties [12,13,15–18]. Although elevated
concentrations of WT b2m are characteristic of DRA [2,3,7],
the relevance of non-fibrillar DN6b2m cytotoxicity is unclear, as
DN6b2m has only been detected in amyloid deposits and is not
found in the serum of hemodialysis patients [15,49]. DN6b2m,
however, has an increased affinity for collagen [50], which could
lead to localized high concentrations of the soluble protein and
resultant cytotoxicity.
The study outlined herein examined how monomeric and
fibrillar b2m affect primary human cells present in the osteo-
articular tissues of subjects with DRA. We have shown previously
that b2m fibrils are cytotoxic to the murine macrophage RAW
264.7 and human neuroblastoma SH-SY5Y cell lines [29],
demonstrating that b2m fibril-associated cytotoxicity is not unique
to monocytes, osteoblasts and chondrocytes. Furthermore, since
fibrillar preparations of other amyloidogenic precursors are also
cytotoxic [29,44–46,51–54], it is likely that these would reduce
viability of monocytes, osteoblasts and chondrocytes. Amyloid
deposits in the osteoarticular tissues can be present in other
amyloid diseases [55,56] and may cause the death of osteoblasts
and chondrocytes. Macrophages and macrophage-like cells
such as microglia are found in association with other forms of
amyloid [57,58]. As such fibril-associated cytotoxicity to macro-
phages and macrophage-like cells could be a factor in other
amyloid diseases.
Figure 6. Model for a role of monomeric and fibrillar b2-microglobulin (b2m) cytotoxicity in dialysis related amyloidosis. (1) Elevated
levels of circulating b2m monomer form amyloid deposits in osteoarticular tissues. (2) Circulating monocytes are able to differentiate into both
macrophages and osteoclasts. (3) Monocyte-derived macrophages infiltrate b2m amyloid deposits, but the resistance of the amyloid fold to
proteolysis in combination with b2m amyloid cytotoxicity, prevents the clearance of the amyloid deposits. (4) b2m amyloid induced monocyte/
macrophage cell death also contributes to reduced osteoclast formation, causing a decrease in the resorption of old bone. (5) Osteoblast cell death in
the presence of b2m monomer and/or fibrils causes decreased bone formation. (6) Decreased bone resorption and formation contribute to
pathological alterations to normal bone homeostasis. (7) Chondrocyte cell death in the presence of b2m monomer and/or fibrils causes decreased
cartilage formation, which could allow gradual loss of this tissue and exposure of bone to cytotoxic b2m monomer and fibrils.
doi:10.1371/journal.pone.0027353.g006
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In conclusion, our observations show that cytotoxicity of
monomeric b2m and b2m fibrils to cell types in the joints of
subjects with DRA could be important factors in the development
of the osteoarticular pathology of this disorder (Fig. 6).
Materials and Methods
Ethics statement
The procedure for the isolation of monocytes from peripheral
blood of healthy volunteers was approved by the Faculty of
Biological Sciences Research Ethics Committee at the University
of Leeds. Written informed consent was given by each donor.
Expression, purification and labelling of b2m
RecombinantWT b2m andDN6b2m were expressed in E. coli and
purified as described previously [12,30,31]. Purification was
confirmed by electrospray ionization mass spectrometry and size
exclusion chromatography, as previously described [17]. Endotoxins
were removed using an ‘‘EndoTrap Red’’ column (Hyglos, Bernreid,
Germany) and Limulus amoebocyte lysate assays performed by
Lonza (Verviers, Belgium) showed endotoxin concentrations to be
#7.35 EU/mg protein. Purified proteins were labelled with TMR
(Molecular Probes, Eugene, OR, USA) using methods described
previously [40]. Further details are provided in File S1.
Generation of b2m fibrils at physiological pH
Fibrils formed at pH 2 [29] were fragmented by freezing in
liquid nitrogen and thawing at 37uC three times to generate fibril
seeds. 5% (v/v) seeds were elongated with 1 mg/ml DN6b2m in
Dulbecco’s Phosphate Buffered Saline (PBS) pH 7.3, at 37uC, with
agitation at 200 rpm in the presence of 0.1 mg/ml low molecular
weight heparin (Sigma-Aldrich H8537), 100 U/ml penicillin and
100 mg/ml streptomycin, for 21 days. To generate labelled fibrils,
seeds were extended with 0.9 mg/ml unlabelled DN6b2m and
0.1 mg/ml TMR-DN6b2m. Fibril concentrations are stated as
monomer equivalents.
TEM, thioflavin-T binding and immunoblotting
Negative stain TEM and thioflavin-T assays were performed as
previously described [17,30]. Immunoblotting with A11 and WO1
antibodies was performed as described previously [32,33,59], and
in detail in File S1.
Isolation and culture of primary human monocytes
Mononuclear cells were isolated from peripheral blood by
centrifugation over Lymphoprep (Axis-Shield, Oslo, Norway),
monocytes were enriched using the MACS monocyte II kit
(Miltenyi Biotec, Bergisch Gladbach, Germany) and enrichment
confirmed by flow cytometric analysis of cells stained with anti-
CD14-Phycoerythrin (Miltenyi Biotec) on a FACSCalibur instru-
ment (BD Biosciences). Monocytes were cultured at 500 000 cells/
cm2, in aMEM supplemented with 10% (v/v) fetal bovine serum
(Biosera, Ringmer, UK), 2 mM L-glutamine, 100 U/ml penicillin,
100 mg/ml streptomycin and 750 ng/ml M-CSF (Peprotech,
Rocky Hill, NJ, USA), at 37uC, 5% CO2.
Culture of primary human chondrocytes and osteoblasts
Primary human osteoblasts, chondrocytes, cell specific media
and an optimized cell detach kit were obtained from PromoCell
(Heidelberg, Germany). Cells were cultured at 10 000–20 000
cells/cm2, in cell specific media supplemented with 100 U/ml
penicillin and 100 mg/ml streptomycin at 37uC, 5% CO2. Cells
were passaged a maximum of three times.
MTT assay of cell viability
Cells were plated in 96 well plates (Corning Inc., Corning, NY,
USA) and cultured overnight. MTT assays were then performed
as described previously [29] and in File S1. For each cell type
MTT assays were performed using the same culture conditions,
enabling each experiment to be internally controlled to exclude
any effects of the growth medium on the reduction of MTT.
Imaging of b2m internalization and degradation
Uptake of 10 mg/ml DN6b2m monomer (90% unlabelled, 10%
TMR labelled) or TMR-DN6b2m fibrils over 24 hours, and
degradation over a further 24 hours was analyzed using methods
described previously [40] and in detail in File S1.
Osteoclast formation and characterization
Primary human monocytes were cultured in 96 well plates
(Corning) or on 16 well osteologic slides (BD Biosciences).
Osteoclast formation was assessed after 14 days by staining for
TRAP and counterstaining with hematoxylin, using a leukocyte
acid phosphatase (TRAP) kit (Sigma-Aldrich 387A) and manu-
facturer’s protocol, and by quantifying the percentage resorption
of the osteologic substrate. Further details are provided in File S1.
Supporting Information
Figure S1 Effects of monomeric and fibrillar b2-micro-
globulin (b2m) on monocyte viability. Primary human
monocytes from three independent donors were treated with the
indicated substances for 24 hours and then their ability to reduce
MTT, as a measure of viability, was measured for each donor. (a)
Effects of DN6b2m (DN6) monomer and b2m fibrils on viability. (b)
Effect of full-length wild type (WT) b2m monomer on viability. Error
bars represent the SEM; P values differing from the PBS control
were calculated by the Student’s t-test, * =P#0.01; **=P#0.001.
(TIFF)
Figure S2 Monomeric and fibrillar b2-microglobulin
(b2m) association with osteoblasts and their effects on
cell viability. (a) Primary human osteoblasts were incubated
with either TMR-labelled DN6b2m monomer or TMR-labelled
b2m fibrils (red) for 24 hours and then imaged by confocal
microscopy. Differential interferance contrast (DIC) images are
also shown. The regions within the white boxes are magnified in
the right hand panels. (b) Cells from four independent donors were
treated with DN6b2m monomer or b2m fibrils for 24 hours and
then their ability to reduce MTT, as a measure of viability, was
measured for each donor. Error bars represent the SEM; P values
differing from the PBS control were calculated by the Student’s t-
test, * = P#0.01; ** = P#0.001.
(TIFF)
Figure S3 Monomeric and fibrillar b2-microglobulin
(b2m) association with chondrocytes and their effects
on cell viability. (a) Primary human chondrocytes were treated
with either TMR-labelled DN6b2m monomer or TMR-labelled
fibrils (red) for 24 hours and then imaged by confocal microscopy.
Differential interferance contrast (DIC) images are also shown.
The regions within the white boxes are magnified in the in the
right hand panels. (b) Chondrocytes from four independent donors
were treated with DN6b2m monomer or b2m fibrils for 24 hours
and then their ability to reduce MTT, as a measure of viability,
was measured for each donor. Error bars represent the SEM; P
values differing from the PBS control were calculated by the
Student’s t-test, * = P#0.01; ** =P#0.001.
(TIFF)
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File S1 Full materials and methods.
(DOC)
Acknowledgments
We thank Gareth Howell for advice on microscopy, James Ault for
performing mass spectrometry, Charles Glabe (University of California,
Irvine) for the A11 antibody and Ab1–40 oligomers, Ron Wetzel (University
of Pittsburg) for the WO1 antibody, and Andrew Hellewell, Toral Jakhria
and Aneika Leney for WT b2m samples. We thank members of the Hewitt
and Radford labs for helpful discussions.
Author Contributions
Conceived and designed the experiments: MYP KER SER EWH.
Performed the experiments: MYP KER. Analyzed the data: MYP KER
SER EWH. Contributed reagents/materials/analysis tools: MYP. Wrote
the paper: MYP KER SER EWH.
References
1. Chiti F, Dobson CM (2006) Protein misfolding, functional amyloid, and human
disease. Annu Rev Biochem 75: 333–366.
2. Floege J, Ehlerding G (1996) b2-microglobulin-associated amyloidosis. Nephron
72: 9–26.
3. Floege J, Ketteler M (2001) b2-microglobulin-derived amyloidosis: an update.
Kidney Int Suppl 78: S164–171.
4. Gorevic PD, Casey TT, Stone WJ, DiRaimondo CR, Prelli FC, et al. (1985) b2-
microglobulin is an amyloidogenic protein in man. J Clin Invest 76: 2425–2429.
5. Gejyo F, Yamada T, Odani S, Nakagawa Y, Arakawa M, et al. (1985) A new
form of amyloid protein associated with chronic hemodialysis was identified as
b2-microglobulin. Biochem Biophys Res Commun 129: 701–706.
6. Heegaard NH (2009) b2-microglobulin: from physiology to amyloidosis.
Amyloid 16: 151–173.
7. Drueke TB, Massy ZA (2009) b2-microglobulin. Semin Dial 22: 378–380.
8. Danesh F, Ho LT (2001) Dialysis-related amyloidosis: history and clinical
manifestations. Semin Dial 14: 80–85.
9. Ohashi K (2001) Pathogenesis of b2-microglobulin amyloidosis. Pathol Int 51:
1–10.
10. Relini A, Canale C, De Stefano S, Rolandi R, Giorgetti S, et al. (2006) Collagen
plays an active role in the aggregation of b2-microglobulin under physiopath-
ological conditions of dialysis-related amyloidosis. J Biol Chem 281:
16521–16529.
11. Relini A, De Stefano S, Torrassa S, Cavalleri O, Rolandi R, et al. (2008)
Heparin strongly enhances the formation of b2-microglobulin amyloid fibrils in
the presence of type I collagen. J Biol Chem 283: 4912–4920.
12. Myers SL, Jones S, Jahn TR, Morten IJ, Tennent GA, et al. (2006) A systematic
study of the effect of physiological factors on b2-microglobulin amyloid
formation at neutral pH. Biochemistry 45: 2311–2321.
13. Borysik AJ, Morten IJ, Radford SE, Hewitt EW (2007) Specific glycosamino-
glycans promote unseeded amyloid formation from b2-microglobulin under
physiological conditions. Kidney Int 72: 174–181.
14. Yamamoto S, Yamaguchi I, Hasegawa K, Tsutsumi S, Goto Y, et al. (2004)
Glycosaminoglycans enhance the trifluoroethanol-induced extension of b2-
microglobulin-related amyloid fibrils at a neutral pH. J Am Soc Nephrol 15:
126–133.
15. Bellotti V, Stoppini M, Mangione P, Sunde M, Robinson C, et al. (1998) b2-
microglobulin can be refolded into a native state from ex vivo amyloid fibrils.
Eur J Biochem 258: 61–67.
16. Esposito G, Michelutti R, Verdone G, Viglino P, Hernandez H, et al. (2000)
Removal of the N-terminal hexapeptide from human b2-microglobulin facilitates
protein aggregation and fibril formation. Protein Sci 9: 831–845.
17. Eichner T, Radford SE (2009) A generic mechanism of b2-microglobulin
amyloid assembly at neutral pH involving a specific proline switch. J Mol Biol
386: 1312–1326.
18. Eichner T, Kalverda AP, Thompson GS, Homans SW, Radford SE (2011)
Conformational conversion during amyloid formation at atomic resolution. Mol
Cell 41: 161–172.
19. Eichner T, Radford SE (2011) Understanding the complex mechanisms of b2-
microglobulin amyloid assembly. FEBS J 278: 3868–83.
20. Inoue H, Saito I, Nakazawa R, Mukaida N, Matsushima K, et al. (1995)
Expression of inflammatory cytokines and adhesion molecules in haemodialysis-
associated amyloidosis. Nephrol Dial Transplant 10: 2077–2082.
21. Argiles A, Mourad G, Kerr PG, Garcia M, Collins B, et al. (1994) Cells
surrounding haemodialysis-associated amyloid deposits are mainly macrophages.
Nephrol Dial Transplant 9: 662–667.
22. Garbar C, Jadoul M, Noel H, van Ypersele de Strihou C (1999) Histological
characteristics of sternoclavicular b2-microglobulin amyloidosis and clues for its
histogenesis. Kidney Int 55: 1983–1990.
23. Kazama JJ, Maruyama H, Gejyo F (2001) Osteoclastogenesis and osteoclast
activation in dialysis-related amyloid osteopathy. Am Journal Kidney Dis 38:
S156–160.
24. Asagiri M, Takayanagi H (2007) The molecular understanding of osteoclast
differentiation. Bone 40: 251–264.
25. Roodman GD (2006) Regulation of osteoclast differentiation. Ann N Y Acad Sci
1068: 100–109.
26. Raggatt LJ, Partridge NC (2010) Cellular and molecular mechanisms of bone
remodeling. J Biol Chem 285: 25103–25108.
27. Kazama JJ, Yamamoto S, Takahashi N, Ito Y, Maruyama H, et al. (2006) Ab-
2M-amyloidosis and related bone diseases. J Bone Miner Metab 24: 182–184.
28. Menaa C, Esser E, Sprague SM (2008) b2-microglobulin stimulates osteoclast
formation. Kidney Int 73: 1275–1281.
29. Xue WF, Hellewell AL, Gosal WS, Homans SW, Hewitt EW, et al. (2009) Fibril
fragmentation enhances amyloid cytotoxicity. J Biol Chem 284: 34272–34282.
30. Kad NM, Thomson NH, Smith DP, Smith DA, Radford SE (2001) b2-
microglobulin and its deamidated variant, N17D form amyloid fibrils with a
range of morphologies in vitro. J Mol Biol 313: 559–571.
31. Ladner CL, Chen M, Smith DP, Platt GW, Radford SE, et al. (2010) Stacked
sets of parallel, in-register b-strands of b2-microglobulin in amyloid fibrils
revealed by site-directed spin labeling and chemical labeling. J Biol Chem 285:
17137–17147.
32. Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, et al. (2003)
Common structure of soluble amyloid oligomers implies common mechanism of
pathogenesis. Science 300: 486–489.
33. O’Nuallain B, Wetzel R (2002) Conformational Abs recognizing a generic
amyloid fibril epitope. Proc Natl Acad Sci U S A 99: 1485–1490.
34. Nishi S, Ogino S, Maruyama Y, Honma N, Gejyo F, et al. (1990) Electron-
microscopic and immunohistochemical study of b2-microglobulin-related
amyloidosis. Nephron 56: 357–363.
35. Inoue S, Kuroiwa M, Ohashi K, Hara M, Kisilevsky R (1997) Ultrastructural
organization of hemodialysis-associated b2-microglobulin amyloid fibrils. Kidney
Int 52: 1543–1549.
36. Jahn TR, Tennent GA, Radford SE (2008) A common beta-sheet architecture
underlies in vitro and in vivo b2-microglobulin amyloid fibrils. J Biol Chem 283:
17279–17286.
37. Gordon S, Taylor PR (2005) Monocyte and macrophage heterogeneity. Nat Rev
Immunol 5: 953–964.
38. Argiles A, Garcia Garcia M, Mourad G (2002) Phagocytosis of dialysis-related
amyloid deposits by macrophages. Nephrol Dial Transplant 17: 1136–1138.
39. Efstratiadis T, Moss DW (1985) Tartrate-resistant acid phosphatase in human
alveolar macrophages. Enzyme 34: 140–143.
40. Morten IJ, Gosal WS, Radford SE, Hewitt EW (2007) Investigation into the role
of macrophages in the formation and degradation of b2-microglobulin amyloid
fibrils. J Biol Chem 282: 29691–29700.
41. Garcia-Garcia M, Argiles Gouin-Charnet A, Durfort M, Garcia-Valero J, et al.
(1999) Impaired lysosomal processing of b2-microglobulin by infiltrating
macrophages in dialysis amyloidosis. Kidney Int 55: 899–906.
42. Hayman AR (2008) Tartrate-resistant acid phosphatase (TRAP) and the
osteoclast/immune cell dichotomy. Autoimmunity 41: 218–223.
43. Malluche HH, Mawad HW, Monier-Faugere MC (2011) Renal osteodystrophy
in the first decade of the new millennium: analysis of 630 bone biopsies in black
and white patients. J Bone Miner Res 26: 1368–1376.
44. Gharibyan AL, Zamotin V, Yanamandra K, Moskaleva OS, Margulis BA, et al.
(2007) Lysozyme amyloid oligomers and fibrils induce cellular death via different
apoptotic/necrotic pathways. J Mol Biol 365: 1337–1349.
45. Rigacci S, Bucciantini M, Relini A, Pesce A, Gliozzi A, et al. (2008) The (1–63)
region of the p53 transactivation domain aggregates in vitro into cytotoxic
amyloid assemblies. Biophys J 94: 3635–3646.
46. Novitskaya V, Bocharova OV, Bronstein I, Baskakov IV (2006) Amyloid fibrils
of mammalian prion protein are highly toxic to cultured cells and primary
neurons. J Biol Chem 281: 13828–13836.
47. Giorgetti S, Raimondi S, Cassinelli S, Bucciantini M, Stefani M, et al. (2009) b2-
microglobulin is potentially neurotoxic, but the blood brain barrier is likely to
protect the brain from its toxicity. Nephrol Dial Transplant 24: 1176–1181.
48. Giorgetti S, Raimondi S, Pagano K, Relini A, Bucciantini M, et al. (2011) Effect
of tetracyclines on the dynamics of formation and destructuration of b2-
microglobulin amyloid fibrils. J Biol Chem 286: 2121–2131.
49. Corlin DB, Sen JW, Ladefoged S, Lund GB, Nissen MH, et al. (2005)
Quantification of cleaved b2-microglobulin in serum from patients undergoing
chronic hemodialysis. Clin Chem 51: 1177–1184.
50. Giorgetti S, Rossi A, Mangione P, Raimondi S, Marini S, et al. (2005) b2-
microglobulin isoforms display an heterogeneous affinity for type I collagen.
Protein Sci 14: 696–702.
51. Dehle FC, Ecroyd H, Musgrave IF, Carver JA (2010) aB-Crystallin inhibits the
cell toxicity associated with amyloid fibril formation by k-casein and the
amyloid-b peptide. Cell stress & chaperones 15: 1013–1026.
52. Lee YJ, Savtchenko R, Ostapchenko VG, Makarava N, Baskakov IV (2011)
Molecular structure of amyloid fibrils controls the relationship between fibrillar
size and toxicity. PloS One 6: e20244.
b2m Mediated Cell Death in DRA
PLoS ONE | www.plosone.org 9 November 2011 | Volume 6 | Issue 11 | e27353
53. Petkova AT, Leapman RD, Guo Z, Yau WM, Mattson MP, et al. (2005) Self-
propagating, molecular-level polymorphism in Alzheimer’s b-amyloid fibrils.
Science 307: 262–265.
54. Mossuto MF, Dhulesia A, Devlin G, Frare E, Kumita JR, et al. (2010) The non-
core regions of human lysozyme amyloid fibrils influence cytotoxicity. J Mol Biol
402: 783–796.
55. Schonland SO, Hansmann J, Mechtersheimer G, Goldschmidt H, Ho AD, et al.
(2008) Bone involvement in patients with systemic AL amyloidosis mimics lytic
myeloma bone disease. Haematologica 93: 955–956.
56. Shiraishi M, Ando Y, Mizuta H, Nakamura E, Takagi K, et al. (1997) Charcot
knee arthropathy with articular amyloid deposition in familial amyloidotic
polyneuropathy. Scand J rheumatol 26: 61–64.
57. Cameron B, Landreth GE (2010) Inflammation, microglia, and Alzheimer’s
disease. Neurobiol Dis 37: 503–509.
58. de Koning EJ, van den Brand JJ, Mott VL, Charge SB, Hansen BC, et al. (1998)
Macrophages and pancreatic islet amyloidosis. Amyloid 5: 247–254.
59. Gosal WS, Morten IJ, Hewitt EW, Smith DA, Thomson NH, et al. (2005)
Competing pathways determine fibril morphology in the self-assembly of b2-
microglobulin into amyloid. J Mol Biol 351: 850–864.
b2m Mediated Cell Death in DRA
PLoS ONE | www.plosone.org 10 November 2011 | Volume 6 | Issue 11 | e27353
